Robert Mendelson, MD
Cardiovascular Disease · Jamaica, NYNPI 1215997267
Payments from drug & device makers
Across 70 payments — averaging $3302.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$141K
- Novartis$90K
- GE HealthCare$67
- Merck$22
- Kiniksa Pharmaceuticals International, PLC$19
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16
Across 1 payment — averaging $656.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$656
What the payments were for
- Travel & lodging$62357%
- Food & beverage$45041%
- Education$222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 61 | $140,898 |
| Novartis | 4 | $90,126 |
| GE HealthCare | 2 | $67 |
| Merck | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
How this compares
$231,148 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $77,635 |
| XareltoRivaroxaban | 60 | $76,434 |
| JardianceEmpagliflozin | 40 | $41,320 |
| Praluent PenAlirocumab | 13 | $6,465 |
| Ranolazine ErRanolazine | 37 | $6,061 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 74 | $4,754 |
| Carvedilol ErCarvedilol Phosphate | 23 | $4,049 |
| Metoprolol Succinate | 155 | $2,917 |
| Valsartan | 57 | $1,694 |
| Candesartan Cilexetil | 22 | $1,617 |
| Verapamil ErVerapamil Hcl | 62 | $1,488 |
| Nifedipine ErNifedipine | 59 | $1,373 |
| ClopidogrelClopidogrel Bisulfate | 66 | $1,120 |
| Atorvastatin Calcium | 86 | $1,088 |
| Ramipril | 58 | $1,047 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Jamaica
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.